SANTA MONICA, Calif., Jan. 20, 2022 (GLOBE NEWSWIRE) — Correction: Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, reports that the company mistakenly reissued the press release this afternoon entitled, “Opiant Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).” This press release is a duplicate of the press release issued on December 20, 2021. The company regrets the error.
For Media and Investor Inquiries:
Ben Atkins, Opiant
(310) 598-5410
batkins@opiant.com
ORLANDO, FL / ACCESS Newswire / December 11, 2025 / Exousia Pro, Inc. (OTCID:MAJI), a…
KENNEWICK, Wash. and HOUSTON, Dec. 11, 2025 /PRNewswire/ -- Cadwell, a global leader in neurodiagnostic…
New embedded solution empowers more than 900,000 small businesses to offer flexible, affordable health coverage directly…
CONSHOHOCKEN, Pa., Dec. 11, 2025 /PRNewswire/ -- Suvoda, a global clinical trial technology company, today announced…
TraceLink announced its support for UNICEF's Traceability and Verification System (TRVST), a global initiative improving…
VISALIA, Calif., Dec. 11, 2025 /PRNewswire/ -- Maison Law Accident & Injury Lawyers announces the…